Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: ASHS provides Gamma Knife stereotactic radiosurgery services to medical centers through its 81% interest in GK Financing, LLC (GKF). The company operates 14 Gamma Knife units across 13 states. Revenue is derived 100% from Gamma Knife services, with two primary contract models: fee-per-use and revenue sharing. The company is also developing a new business model ("OR21") but it is not expected to generate significant revenue in the near term.
Key Financial Metrics (Year Ended Dec 31, 2002)
| Metric | 2002 | 2001 | 2000 |
|---|---|---|---|
| Medical Services Revenue | $13,366,000 | $11,758,000 | $9,336,000 |
| Net Income | $1,102,000 | $1,068,000 | $1,312,000 |
| Earnings Per Share (Basic) | $0.30 | $0.30 | $0.34 |
| Operating Cash Flow | $4,188,000 | $4,166,000 | $2,515,000 |
| Total Assets | $44,830,000 | $42,385,000 | $40,209,000 |
| Total Debt (Long-term + Current) | $27,496,000 | $25,920,000 | $24,426,000 |
| Cash and Cash Equivalents | $9,924,000 | $11,580,000 | $12,421,000 |
| Working Capital | $7,175,000 | $9,351,000 | $10,155,000 |
Margins: Operating margin was approximately 16.6% ($2.217M / $13.366M). Net profit margin was approximately 8.2%.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13.7% to $13.366 million, driven by the addition of two new Gamma Knife units in 2002 and increased volume at existing sites. The number of procedures rose 16.6% to 1,696.
- Costs of Operations: Increased 26.0% to $5.399 million (40.4% of revenue), primarily due to higher depreciation from new units and increased maintenance costs as warranties expired on older units.
- Interest Expense: Decreased slightly by 0.8% to $2.437 million, as lower interest on mature loans offset the cost of financing new units.
- Interest Income: Declined 64.4% to $171,000 due to lower market interest rates and reduced cash balances.
- Dividends: The company paid $438,000 in dividends in 2002 ($0.12 per share), continuing the policy initiated in 2001.
- Working Capital: Decreased by $2.176 million to $7.175 million, primarily due to a reduction in cash and an increase in the current portion of long-term debt.
Outlook, Risks, and Management Commentary
Outlook and Guidance: Management anticipates continued profitability and the ability to service cash requirements in 2003 using existing cash and working capital. The company plans to continue financing Gamma Knife units with debt. Three additional sites are under development, with two projected to be operational by mid-2003.
Key Risks:
- Reimbursement Rates: Revenue is sensitive to Medicare and Medicaid reimbursement rates. The implementation of Ambulatory Product Classifications (APC) reduced outpatient reimbursement by approximately 40% historically, though the company expects limited impact in 2002. Future rate reductions could adversely affect revenue.
- Capital Intensity and Debt: The business is highly leveraged with $27.5 million in debt collateralized by Gamma Knife units. Default could lead to asset seizure.
- Competition: Competition exists from Elekta (the manufacturer), other financing providers, and alternative technologies like linear accelerators.
- Customer Concentration: Two customers (Yale and UAMS) accounted for more than 10% of revenue in 2002.
- Regulatory Compliance: Risks associated with federal anti-kickback statutes, Stark II (physician self-referral), and False Claims Act.
Unusual Items: The company recorded a $168,000 income tax benefit in 2002 from the exercise of stock options, which reduced the effective tax provision.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the 6-to-1 debt-to-equity ratio required by lenders for future funding of the three sites under development.
- Reimbursement Trends: Monitor Medicare APC rate changes and their specific impact on the two revenue-sharing contracts (Yale and UAMS) and any future outpatient shifts.
- Customer Concentration: Assess the stability of the top two customers, which collectively represent a significant portion of total revenue.
- Capital Expenditures: Confirm the timeline and funding status for the three Gamma Knife units under development, which require approximately $5.4 million in remaining cash.
- Stock Option Dilution: Review the impact of the 1.423 million vested options outstanding on future earnings per share.